Azenosertib

Phase 3Small molecule

KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.

Azenosertib is one of 103 small molecule programs targeting Ovarian Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

102

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ovarian CancerRecruiting

PembrolizumabActive, not recruiting

Primary Peritoneal CancerRecruiting

Serous CarcinomaCompleted

Locally Advanced Pancreatic Ductal AdenocarcinomaRecruiting

Ovarian CancerPhase 3

Recruiting

PembrolizumabPhase 2

Active, not recruiting

Primary Peritoneal CancerPhase 2

Recruiting

Serous CarcinomaPhase 2

Completed

Locally Advanced Pancreatic Ductal AdenocarcinomaPhase 1

Recruiting

Competition

Competitive Landscape

209 competitors in Ovarian Cancer

#DrugCompanyPhaseTrials

Avastin

Roche

Phase 3

92 2

Hycamtin

MMeitheal

Phase 3

26 3

Pegylated Liposomal Doxorubicin

Merck & Co.

Phase 3

35 4

Imfinzi

AstraZeneca

Phase 3

8 5

Opdivo

Bristol-Myers Squibb

Phase 3

8 6

Adriamycin

Pfizer

Phase 3

8 7

Rubraca

Bristol-Myers Squibb

Phase 3

6 8

Herceptin

Roche

Phase 3

3 9

Zepzelca

Jazz Pharmaceuticals

Phase 3

2 10

Nolvadex

AstraZeneca

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Primary Peritoneal Cancer

NCT05128825

Q3 2027

Phase 1Recruiting

Clinical Stage III Gastric Cancer AJCC V8

NCT06364410

Q1 2028

Phase 2Recruiting

Serous Carcinoma

NCT06369155

Phase 1Recruiting

Locally Advanced Pancreatic Ductal Adenocarcinoma

NCT04005690

Q3 2029

Phase 1/2Active, not recruiting

Pembrolizumab

NCT06351332

Clinical

Trials by Indication[1]

Serous Carcinoma2 trials

Azenosertib in Uterine Serous Carcinoma: Biomarker Study

Recruiting·—·Phase 2·NCT06369155·25 enrolled

A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma

Completed·KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.·Phase 2·NCT04814108·92 enrolled

Active, not recruiting·FFilipa Lynce, MD·Phase 1/2·NCT06351332·78 enrolled

Osteosarcoma1 trial

A Study of Azenosertib (ZN-c3) in Combination With Gemcitabine in Subjects With Osteosarcoma

Completed·KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.·Phase 1/2·NCT04833582·31 enrolled

3 more indications

Primary Peritoneal Cancer1 trial

A Phase 2 Open-Label, Multicenter Study To Evaluate Efficacy And Safety Of ZN-c3 In Subjects With High-Grade Serous Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer (DENALI / ZN-c3-005 / GOG-3066)

Recruiting·KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.·Phase 2·NCT05128825·310 enrolled

Clinical Stage III Gastric Cancer AJCC v81 trial

Phase 1 Study of Trastuzumab Deruxtecan (DS-8201a) in Combination With Azenosertib (ZN-c3) in HER2-Expressing/Amplified Gastric/Gastroesophageal Junction Cancer and Other Solid Tumors

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT06364410·48 enrolled

Locally Advanced Pancreatic Ductal Adenocarcinoma1 trial

A Window of Opportunity Strategy for Targeted Pathway Inhibition in Patients With Pancreatic Ductal Adenocarcinoma

Recruiting·OOHSU Knight Cancer Institute·Phase 1·NCT04005690·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Azenosertib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Azenosertib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Azenosertib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.

Azenosertib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2027

Q1 2028

Q3 2029

Trials by Indication[1]

Serous Carcinoma2 trials

Ovarian Cancer2 trials

Solid Tumors1 trial

Pembrolizumab1 trial

Osteosarcoma1 trial

Primary Peritoneal Cancer1 trial

Clinical Stage III Gastric Cancer AJCC v81 trial

Locally Advanced Pancreatic Ductal Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News